CA-COMEXPOSIUM
19.2.2015 15:01:33 CET | Business Wire | Pressemeddelelse
The Comexposium Group, one of the largest trade show and conference companies in the world, has acquired Mobile Motion LLC, the company responsible for organising Mobile Media Summit events in the United States and Europe. Paran Johar, the founder of the Los Angeles-based company, remains its CEO. The terms of the acquisition are undisclosed.
Mobile Media Summits are the quintessential thought-leadership forums for brand, agency and mobile leaders to share learnings and network on the newest mobile technology. The network is the largest mobile media and advertising conference series in North America and has been growing rapidly in Europe for the past two years, with shows in Barcelona, London and Cannes.
With mobile industry earnings forecast to leap 45% between 2013 and 2020 (according to GSMA Intelligence), to reach a record high of US $2.9 trillion, Mobile Media Summit events are established in a booming market.
Comexposium’s investment in the mobile industry will allow the group to add 10 international events to its portfolio. Upcoming conferences include:
Mobile Media Summit @ Mobile World Congress – 4th
March 2015
– Barcelona
Mobile Media Summit Los Angeles – 7th
April
2015
Mobile Media Summit @ NY Upfronts - 18th
May 2015 –
New York
Mobile Media Summit London – 16th
June 2015
Mobile
Mafia at Cannes International Festival of Creativity 23rd
to
25th
June 2015
Mobile Media Summit Chicago – 28th
July 2015
Mobile Media during NY Advertising Week – 28th
September 2015 – New York
Mobile Minds @ Art Basel – 1st
and 2nd
December 2015 - Miami
Renaud Hamaide, Comexposium’s Managing Director, says: “This rapidly growing industry is integral to the group’s international development strategy and represents a portfolio of leading events that will work in synergy with our existing ones.”
“I am incredibly excited to expand our Mobile Media Summit conferences around the world. With mobile becoming the cornerstone of marketing, advertising, and technology, our events have become critical for brands, agencies and media companies that want to stay ahead of the curve in business,” said Paran Johar CEO and Founder of the Mobile Media Summit.
According to leading industry analyst Forrester, mobile reached a tipping point in 2014 as it solidified its position as one of the most disruptive technologies for businesses in decades. Forrester also recently predicted that a record 42% of the total population globally will own a smartphone by the end of 2015.
The Jordan, Edmiston Group, Inc., the New York-based investment bank focused on the media, information, marketing and technology sectors, represented Mobile Motion, LLC in this transaction and acted as its exclusive financial advisor.
About Comexposium
Comexposium, one of the European leaders in event organization, is
involved in 114 events for the general public and professionals,
covering 17 different sectors of activity. Every year it plays host to
38,000 exhibitors, 40% of which are from outside France, and 3.5 million
visitors, including 350,000 visitors from abroad. Internationaly, today
Comexposium is : Cartes Secure Connexions America - Cartes Secure
Connexions Asia - CURVExpo New York - CURVExpo Las Vegas – Djazagro –
Djazagri - Equip Auto Alger - Equipmag Retail Expo China – Expovinis –
Fast Fashion Tour London - Global Security Asia - Hong-Kong mode
lingerie - Interfilière Hong-Kong - Interfilière Shanghai - Milipol
Qatar - SET Canada - Shanghai mode lingerie - SIAL ASEAN - SIAL China -
SIAL Brazil - SIAL Middle East - SIAL Canada - SIAL Interfood Jakarta -
SILMO Istanbul – SIMA ASEAN - Sitevinitech Argentina - Sitevinitech
China - Techno Security & Mobile Forensics World.
Visit www.comexposium.com
for more information.
About Mobile Motion, LLC.
Mobile Motion LLC is the founder of Mobile Media Summit, the quintessential thought-leadership forum for top executives in advertising, media, publishing, and the hottest brand marketers. The Summits focus on the intersection of mobile advertising and technology, covering the most important issues in mobile and are often home to breaking news and advances in the space. Founded in 2009 by Paran Johar, Mobile Media Summits are the largest event series in mobile advertising, where an average of 75% of the audience are advertisers, more than any other event. Since its founding, the event series has hosted over 2,500 speakers and well over 15,000 attendees. Visit www.mobilemediasummit.com for more information.
Contact:
Pierre Barbe, +33 (1) 76 77 11 41
Comexposium – Corporate
Communication
pierre.barbe@comexposium.com
or
Adrienne
Scordato, 917.402.5377
Atrium PR
adrienne@atrium-pr.com
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum